Changes in Hong Kong stocks | Hutchison Pharmaceuticals (00013) rose more than 3% in clinical studies using solepinib to treat warm-antibody autoimmune hemolytic anemia with positive results

The Zhitong Finance App learned that Hewang Pharmaceutical (00013) rose by more than 3%. As of press release, it had risen 3.1% to HK$21.98, with a turnover of HK$44.32,300.

According to the news, on January 7, Hehuang Pharmaceutical announced that the phase III registration phase of the ESLIM-02 study on the novel spleen tyrosine kinase (Syk) inhibitor solepinib for the treatment of adult patients with warm-antibody autoimmune hemolytic anemia has reached the main end point of long-lasting hemoglobin (Hb) response during the 5th to 24 weeks of treatment.

The ESLIM-02 study is a randomized, double-blind, placebo-controlled phase II/III clinical trial in adult patients with primary or secondary warm-antibody autoimmune hemolytic anemia who have relapsed or are refractory after receiving at least one standard treatment in the past. The results of phase II of the study were published in “The Lancet Haematology (The Lancet Haematology)” in January 2025.

The full data from the ESLIM-02 study will be presented at an upcoming academic conference. In the first half of 2026, Hehuang Pharmaceutical plans to submit a marketing application for solepinib as a new drug for the treatment of warm-antibody autoimmune hemolytic anemia to the China National Drug Administration (CFDA).